Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics's investors include National Institutes of Health, Florida Opportunity Fund, National Institute for Health and Care Research, JSR Life Sciences.
Aqualung Therapeutics is headquartered in Tucson, United States.
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aqualung Therapeutics — Funding & Investors." VCBacked, April 4, 2023, https://www.vcbacked.co/company/aqualung-therapeutics. Accessed October 31, 2026.
VCBacked. (2023). Aqualung Therapeutics — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/aqualung-therapeutics
{{cite web |title=Aqualung Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aqualung-therapeutics |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated